Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

A. Gesierich · SciRah

Researcher profile · Semantic Scholar

A. Gesierich

Share profile

A. Gesierich — researcher profile on SciRah

h-index: 30
Works: 137
Citations: 5,624

Most-cited papers

Systematic outperformance of 112 dermatologists in multiclass skin cancer image classification by convolutional neural networks.
Roman C. Maron, M. Weichenthal, J. Utikal, A. Hekler +19 more
2019European Journal of Cancer212 citations Open access
Semantic Scholar
Dermatologist-like explainable AI enhances trust and confidence in diagnosing melanoma
T. Chanda, Katja Hauser, S. Hobelsberger, Tabea-Clara Bucher +120 more
2023Nature Communications181 citations Open access
Semantic Scholar
Combined immune checkpoint blockade for metastatic uveal melanoma: a retrospective, multi-center study
M. Heppt, T. Amaral, K. Kähler, L. Heinzerling +18 more
2019Journal of Immunotherapy for Cancer125 citations Open access
Semantic Scholar
Ipilimumab in metastatic melanoma patients with pre-existing autoimmune disorders
K. Kähler, T. Eigentler, A. Gesierich, L. Heinzerling +10 more
2018Cancer Immunology and Immunotherapy114 citations Open access
Semantic Scholar
Hematological immune related adverse events after treatment with immune checkpoint inhibitors.
Rafaela Kramer, A. Zaremba, Alvaro Moreira, S. Ugurel +29 more
2021European Journal of Cancer98 citations
Semantic Scholar
Combined immunotherapy with nivolumab and ipilimumab with and without local therapy in patients with melanoma brain metastasis: a DeCOG* study in 380 patients
T. Amaral, F. Kiecker, S. Schaefer, H. Stege +27 more
2020Journal for ImmunoTherapy of Cancer85 citations Open access
Semantic Scholar
Prognosis of Patients With Primary Melanoma Stage I and II According to American Joint Committee on Cancer Version 8 Validated in Two Independent Cohorts: Implications for Adjuvant Treatment
C. Garbe, U. Keim, T. Amaral, C. Berking +23 more
2022Journal of Clinical Oncology82 citations Open access
Semantic Scholar
Therapeutic Value of Sentinel Lymph Node Biopsy in Patients With Melanoma: A Randomized Clinical Trial.
J. Crystal, John F. Thompson, J. Hyngstrom, C. Caracò +58 more
2022JAMA Surgery64 citations Open access
Semantic Scholar
Second-line therapies for steroid-refractory immune-related adverse events in patients treated with immune checkpoint inhibitors.
T. Ruf, Rafaela Kramer, A. Forschner, U. Leiter +15 more
2024European Journal of Cancer55 citations Open access
Semantic Scholar
Prognosis of Patients With Stage III Melanoma According to American Joint Committee on Cancer Version 8: A Reassessment on the Basis of 3 Independent Stage III Melanoma Cohorts
C. Garbe, U. Keim, S. Suciu, T. Amaral +17 more
2020Journal of Clinical Oncology55 citations Open access
Semantic Scholar
Chemotherapy after immune checkpoint inhibitor failure in metastatic melanoma: a retrospective multicentre analysis.
S. Goldinger, K. Buder-Bakhaya, S. Lo, A. Forschner +36 more
2021European Journal of Cancer51 citations Open access
Semantic Scholar
Efficacy and Safety of the Melphalan/Hepatic Delivery System in Patients with Unresectable Metastatic Uveal Melanoma: Results from an Open-Label, Single-Arm, Multicenter Phase 3 Study
J. Zager, M. Orloff, P. F. Ferrucci, Jun-Sung Choi +22 more
2024Annals of Surgical Oncology48 citations Open access
Semantic Scholar
Activity of ipilimumab plus nivolumab in avelumab-refractory Merkel cell carcinoma
V. Glutsch, H. Kneitz, A. Gesierich, M. Goebeler +4 more
2021Cancer Immunology and Immunotherapy43 citations Open access
Semantic Scholar
Long-Term Outcomes in BRAF-Mutated Melanoma Treated with Combined Targeted Therapy or Immune Checkpoint Blockade: Are We Approaching a True Cure?
P. Schummer, B. Schilling, A. Gesierich
2020American Journal of Clinical Dermatology42 citations Open access
Semantic Scholar
First-line therapy-stratified survival in BRAF-mutant melanoma: a retrospective multicenter analysis
B. Schilling, A. Martens, M. H. Geukes Foppen, C. Gebhardt +16 more
2019Cancer Immunology and Immunotherapy39 citations Open access
Semantic Scholar
Characteristics of immune checkpoint inhibitor-induced encephalitis and comparison with HSV-1 and anti-LGI1 encephalitis: A retrospective multicentre cohort study.
L. Müller-Jensen, S. Zierold, J. Versluis, Wolfgang Boehmerle +29 more
2022European Journal of Cancer36 citations Open access
Semantic Scholar
Efficacy of PD-1-based immunotherapy after radiologic progression on targeted therapy in stage IV melanoma.
S. Kreft, A. Gesierich, T. Eigentler, C. Franklin +10 more
2019European Journal of Cancer36 citations
Semantic Scholar
Immune Checkpoint Blockade for Metastatic Uveal Melanoma: Patterns of Response and Survival According to the Presence of Hepatic and Extrahepatic Metastasis
Elias A T Koch, A. Petzold, A. Wessely, E. Dippel +28 more
2021Cancers30 citations Open access
Semantic Scholar
Ipilimumab plus nivolumab in avelumab-refractory Merkel cell carcinoma: a multicenter study of the prospective skin cancer registry ADOREG
V. Glutsch, P. Schummer, H. Kneitz, A. Gesierich +12 more
2022Journal for ImmunoTherapy of Cancer26 citations Open access
Semantic Scholar
Virus variant–specific clinical performance of SARS coronavirus two rapid antigen tests in point-of-care use, from November 2020 to January 2022
I. Wagenhäuser, Kerstin Knies, D. Hofmann, Vera Rauschenberger +29 more
2022Clinical Microbiology and Infection25 citations Open access
Semantic Scholar
Neoadjuvant immunotherapy with combined ipilimumab and nivolumab in patients with melanoma with primary or in transit disease
Judith Weber, V. Glutsch, E. Geissinger, L. Haug +6 more
2019British Journal of Dermatology25 citations Open access
Semantic Scholar
Grade 4 Neutropenia Secondary to Immune Checkpoint Inhibition — A Descriptive Observational Retrospective Multicenter Analysis
A. Zaremba, Rafaela Kramer, V. DeTemple, S. Bertram +35 more
2021Frontiers in Oncology22 citations Open access
Semantic Scholar
Response to combined ipilimumab and nivolumab after development of a nephrotic syndrome related to PD-1 monotherapy
V. Glutsch, F. Grän, Judith Weber, A. Gesierich +2 more
2019Journal of Immunotherapy for Cancer21 citations Open access
Semantic Scholar
The identification of patient‐specific mutations reveals dual pathway activation in most patients with melanoma and activated receptor tyrosine kinases in BRAF/NRAS wild‐type melanomas
S. Appenzeller, A. Gesierich, A. Thiem, A. Hufnagel +19 more
2019Cancer19 citations Open access
Semantic Scholar
Liver-directed treatment is associated with improved survival and increased response to immune checkpoint blockade in metastatic uveal melanoma: results from a retrospective multicenter trial
Elias A T Koch, A. Petzold, A. Wessely, E. Dippel +22 more
2023Frontiers in Medicine17 citations Open access
Semantic Scholar
Impact of a preceding radiotherapy on the outcome of immune checkpoint inhibition in metastatic melanoma: a multicenter retrospective cohort study of the DeCOG
S. Knispel, A. Stang, L. Zimmer, H. Lax +25 more
2020Journal for ImmunoTherapy of Cancer17 citations Open access
Semantic Scholar
Correction to: Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update of the pivotal ERIVANCE BCC study
A. Sekulic, M. Migden, N. Basset-Seguin, C. Garbe +13 more
2019BMC Cancer16 citations Open access
Semantic Scholar
Clinical course of Merkel cell carcinoma: A DeCOG multicenter study of 1049 patients.
G. Lodde, U. Leiter, A. Gesierich, T. Eigentler +16 more
2025European Journal of Cancer15 citations
Semantic Scholar
Clinical validation and assessment of feasibility of volumetric absorptive microsampling (VAMS) for monitoring of nilotinib, cabozantinib, dabrafenib, trametinib, and ruxolitinib.
S. Zimmermann, Fatemeh Aghai-Trommeschlaeger, S. Kraus, G. Grigoleit +8 more
2023Journal of Pharmaceutical and Biomedical Analysis15 citations
Semantic Scholar
Age as key factor for pattern, timing, and extent of distant metastasis in patients with cutaneous melanoma: A study of the German Central Malignant Melanoma Registry
M. Gassenmaier, U. Keim, U. Leiter, T. Eigentler +7 more
2019Journal of American Academy of Dermatology15 citations
Semantic Scholar
Early switch from run-in treatment with vemurafenib plus cobimetinib to atezolizumab after 3 months leads to rapid loss of tumour control in patients with advanced BRAFV600-positive melanoma: The ImmunoCobiVem phase 2 randomised trial.
E. Livingstone, H. Gogas, L. Kandolf-Sekulovic, F. Meier +20 more
2023European Journal of Cancer13 citations
Semantic Scholar
PRAME Expression as Helpful Immunohistochemical Marker in Rhabdoid Melanoma
V. Glutsch, M. Wobser, B. Schilling, A. Gesierich +2 more
2022Dermatopathology13 citations Open access
Semantic Scholar
Immune Checkpoint Blockade for Metastatic Uveal Melanoma: Re-Induction following Resistance or Toxicity
Elias A T Koch, A. Petzold, A. Wessely, E. Dippel +27 more
2022Cancers13 citations Open access
Semantic Scholar
A phase II, multicenter study of encorafenib/binimetinib followed by a rational triple-combination after progression in patients with advanced BRAF V600-mutated melanoma (LOGIC2).
R. Dummer, S. Sandhu, W. Miller, M. Butler +15 more
202013 citations
Semantic Scholar
SARS-CoV-2 antigen rapid detection tests: test performance during the COVID-19 pandemic and the impact of COVID-19 vaccination
I. Wagenhäuser, Kerstin Knies, T. Pscheidl, M. Eisenmann +18 more
2024medRxiv12 citations Open access
Semantic Scholar
Multimodal treatment and immune checkpoint inhibition in sinonasal mucosal melanoma: real-world data of a retrospective, single-center study
Agmal Scherzad, Manuel Stöth, T. Meyer, L. Haug +7 more
2023European Archives of Oto-Rhino-Laryngology12 citations Open access
Semantic Scholar
MAPKinase inhibition after failure of immune checkpoint blockade in patients with advanced melanoma - An evaluation of the multicenter prospective skin cancer registry ADOREG.
S. Kreft, V. Glutsch, A. Zaremba, P. Schummer +26 more
2022European Journal of Cancer12 citations Open access
Semantic Scholar
Monitoring of Dabrafenib and Trametinib in Serum and Self-Sampled Capillary Blood in Patients with BRAFV600-Mutant Melanoma
N. Isberner, A. Gesierich, D. Balakirouchenane, B. Schilling +7 more
2022Cancers12 citations Open access
Semantic Scholar
Percutaneous hepatic perfusion (PHP) with melphalan for patients with ocular melanoma liver metastases: Preliminary results of FOCUS (PHP-OCM-301/301A) phase III trial.
J. Zager, M. Orloff, P. Ferrucci, E. Glazer +12 more
2021Journal of Clinical Oncology12 citations
Semantic Scholar
Breaking Avelumab Resistance with combined Ipilimumab and Nivolumab in Metastatic Merkel Cell Carcinoma?
V. Glutsch, Hermann Kneitz, Matthias Goebeler, A. Gesierich +1 more
2019Annals of Oncology12 citations Open access
Semantic Scholar
Blood Eosinophils Are Associated with Efficacy of Targeted Therapy in Patients with Advanced Melanoma
Simone Wendlinger, J. Wohlfarth, S. Kreft, C. Siedel +10 more
2022Cancers11 citations Open access
Semantic Scholar
Avelumab plus cetuximab in patients with unresectable stage III or IV cutaneous squamous cell carcinoma - clinical activity and safety results from AliCe, a single-arm, multicentre phase 2 DeCOG trial.
Jürgen C. Becker, A. Gesierich, U. Leiter, L. Zimmer +13 more
2025British Journal of Dermatology10 citations
Semantic Scholar
An Open-label, Randomized Study of Melphalan/Hepatic Delivery System Versus Best Alternative Care in Patients with Unresectable Metastatic Uveal Melanoma
J. Zager, M. Orloff, P. F. Ferrucci, Jun-Sung Choi +22 more
2025Annals of Surgical Oncology9 citations Open access
Semantic Scholar
Neoadjuvant ipilimumab plus nivolumab in locally advanced melanoma: A real-world single-centre retrospective study
P. Schummer, V. Glutsch, L. Haug, M. Rosenfeldt +8 more
2023EJC Skin Cancer9 citations Open access
Semantic Scholar
Infliximab is a safe and effective treatment in steroid-refractory immune-related hepatitis
K. Oliva, Lisa Arnold, L. Heinzerling, F. Meier +9 more
2025Journal for ImmunoTherapy of Cancer7 citations Open access
Semantic Scholar
Optimizing immune checkpoint blockade in metastatic uveal melanoma: exploring the association of overall survival and the occurrence of adverse events
Elias A T Koch, A. Petzold, E. Dippel, M. Erdmann +23 more
2024Frontiers in Immunology7 citations Open access
Semantic Scholar
1087MO A single arm phase II, multicenter trial to evaluate the clinical activity and safety of avelumab plus cetuximab in unresectable stage III or IV cutaneous squamous cell carcinoma: First results from the AliCe study
J. Becker, B. Schilling, U. Leiter-Stoppke, L. Zimmer +12 more
2023Annals of Oncology7 citations
Semantic Scholar
Efficacy and safety of sequencing with vemurafenib (V) plus cobimetinib (C) followed by atezolizumab (Atezo) in patients (pts) with advanced BRAFV600-positive melanoma: Interim analysis of the ImmunoCobiVem study.
D. Schadendorf, H. Gogas, Lidija Kandolf Sekulovič, F. Meier +16 more
2022Journal of Clinical Oncology7 citations
Semantic Scholar
Bullous pemphigoid developing upon immune checkpoint inhibition with nivolumab
F. Grän, M. Goebeler, A. Gesierich
2019EJD. European journal of dermatology7 citations Open access
Semantic Scholar
Comparison of a newly developed high performance liquid chromatography method with diode array detection to a liquid chromatography tandem mass spectrometry method for the quantification of cabozantinib, dabrafenib, nilotinib and osimertinib in human serum - Application to therapeutic drug monitorin
Fatemeh Aghai-Trommeschlaeger, S. Zimmermann, A. Gesierich, C. Kalogirou +7 more
2022Clinical Biochemistry6 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

F. Meier×19
Invite
F. Meier — researcher profile on SciRah
D. Schadendorf×16
Invite
D. Schadendorf — researcher profile on SciRah
J. Hassel×14
Invite
J. Hassel — researcher profile on SciRah
K. Kähler×13
Invite
K. Kähler — researcher profile on SciRah

×13

Invite

S. Ugurel — researcher profile on SciRah

Invite

C. Berking — researcher profile on SciRah

S. Haferkamp×12

Invite

S. Haferkamp — researcher profile on SciRah

B. Schilling×12

Invite

B. Schilling — researcher profile on SciRah

Invite

L. Zimmer — researcher profile on SciRah

Invite

R. Gutzmer — researcher profile on SciRah

Invite

J. Utikal — researcher profile on SciRah

Invite

U. Leiter — researcher profile on SciRah